Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You have no shot at making money on this stock
it is being quoted on the pink sheets as VLCO. they need to file a 15 c 211 to get back on the otcbb.
no. i think the company is in the process of getting relisted on the otcbb. they are on pink right now.
Great news for VLCO
Here is a link to the show www.mgmlegrand.com
Positron received Frost Sullivan Award for 2010 New Product Innovatiion
Link to Frost Sullivan :http://www.frost.com/prod/servlet/frost-home.pag
i have forwarded it on to the appropriate party
thanks
Here is the next 2 months schedule for POSC at tradeshows
Greater New York Chapter
http://www.snm.org March 4-6, 2010 Taj Mahal Resort
Atlantic City, NJ
Booth #31
PNW Chapter SNM
http://www.snm.org March 13-14, 2010 Embassy Suites Hotel
Portland, OR
Booth TBD
ACC
American College of Cardiology
http://www.acc.org March 14-16, 2010 Georgia World Congress Center Atlanta, GA
Booth #863
SW Chapter SNM
http://www.snm.org
March 19 – 21, 2010 Renaissance Worthington Fort Worth, TX
Booth #8
Central Chapter SNM
http://www.snm.org
March 26-28, 2010 Grand Wayne Convention Center
Fort Wayne, IN
Booth TBD
Mid Eastern Chapter SNM
http://www.snm.org April 9-11, 2010 Marriott Conference Center Hyattsville, MD
Booth TBD
Pittsburgh Chapter SNM
http://www.snm.org April 10, 2010 Regional Learning Alliance Cranberry Woods, PA
Booth TBD
Nuclear Cardiology for the Office Based Practice ASNC April 16-18, 2010 Philadelphia, PA
Booth TBD
MedAxiom Spring Conference
http://www.medaxiom.com April 16-18, 2010 Gaylord National Hotel & Convention Center
Washington D.C.
Florida Nuclear Medical Tech Meeting April 29-May 2, 2010 Renaissance Tampa Tampa, FL
Most important point from 3/1/10 releaae...
John A. Zehner, Positron Corporation, COO and Radiation Safety Officer. “The ability to handle radioactive material will enhance our sales efforts, allow new revenue streams, as well as, offer new opportunities to partner with pharmaceutical companies, Government agencies, inventors and universities.”
The RAM liscense is huge. I don't think the average person sees the potetial for padio pahrmacuetical sales. Especially if the can find an established and compatible partner to work with
Sales just keep coming!!!!
is anyone still following this one?
The company appears to be current in al its filings as of 3/3/2010
looking at a level 2....after .08 and .09 it looks like there is very few shares in the way up to .20
steady daily volume gets this going quickly
good things going on. should be news out soon
Great news out on POSC
I think this opens the door for huge revenue.
INDIANAPOLIS--(BUSINESS WIRE)--Positron Corporation (OTCBB:POSC - News) a molecular imaging solutions company focused on Nuclear Cardiology, announced today that the Nuclear Regulatory Commission has licensed the Positron facility in Fishers, Indiana to handle radioactive material. Positron Corporation and staff demonstrated the necessary expertise and protocol to receive this license. A radioactive material handling license allows Positron to test equipment and develop new technologies, including pharmaceuticals. “A radioactive material license directly benefits our current product line and increases our ability to deliver new technologies,” stated John A. Zehner, Positron Corporation, COO and Radiation Safety Officer. “The ability to handle radioactive material will enhance our sales efforts, allow new revenue streams, as well as, offer new opportunities to partner with pharmaceutical companies, Government agencies, inventors and universities.”
We are going to start accumulationg this week. good luck to all fellow investors!
Anyone been following this stock over the last year?
There have been some decent news releases over the past 6 months.
Looks like volume is picking up. Bid support needed!
put out some news already
c smiley
wow $280 of buying
dead in the water
Three Year High in EBITDA for Positron
08/26/2009
New York, NY, August 26, 2009-EbitdaEXTRA reports that negative EBITDA for Positron Corporation (OTC:POSC) for its quarter ended June 30, 2009 was $(492,000), a 19.6% improvement over the year earlier same quarter when Positron generated $(612,000) in negative EBITDA. Positron has generated twenty-five consecutive quarters of negative EBITDA. EBITDA for the most recent quarter also reached a three year high.
For Positron's twelve months ended June 30, 2009 EBITDA was $(5,937,000), compared with $(6,759,000), a 12.2% improvement over the comparable year earlier twelve months.
The shares of Positron were recently trading at $0.08 which is within 6% of their one year high of $0.09 on August 29, 2008.
EBITDA defined by EbitdaEXTRA:
EBITDA (Earnings Before Interest Taxes Depreciation & Amortization) is calculated by taking Operating Income and adding or subtracting depreciation and/or amortization.
EbitdaEXTRA is the primary "EBITDA" news source for over 8,000 public companies for monitoring and reporting on EBITDA.
EbitdaEXTRA, in publishing over 30,000 stories per year related to EBITDA, is the leading global source for EBITDA related news. EbitdaEXTRA�s company news, industry news and archives are available at www.StockTrendNews.com.
Positron's Free Cash Flow Hits Five Year High
08/24/2009
New York, NY, August 24, 2009-FreeCashNews.com reports that negative Free Cash Flow for Positron Corporation (OTC:POSC) for its quarter ended June 30, 2009 was $(549,000), a 46% improvement over the year earlier same quarter when Positron generated $(1,022,000) in negative Free Cash Flow. Positron has generated twenty-one consecutive quarters of negative Free Cash Flow. Free Cash Flow for the most recent quarter also reached a five year high.
For Positron's twelve months ended June 30, 2009 Free Cash Flow was $(2,677,000), compared with $(3,483,000), a 23% improvement over the comparable year earlier twelve months.
The shares of Positron were recently trading at $0.08 which is within 6% of their one year high of $0.09 on August 29, 2008.
The FreeCashNews.com utilizes the following definition or calculation for its published Free Cash Flow news and reports:
Free cash flow is defined as cash flow from operations or operating cash flow plus or minus capital expenditures. "Capital Expenditures" is a line item, which can be found in the Cash Flow From Investments section of a company's Cash Flow Statement which is filed quarterly in the 10Q and 10K reports with the U.S. Securities & Exchange Commission by publicly traded companies.
FreeCashNews.com publishes quarterly updates on Free Cash Flow for approximately 8,200 publicly traded U.S. companies. It also monitors and publishes news and special reports on 216 industry groups. More information on FreeCashNews.com is available at www.StockTrendNews.com.
Cash Flow from Operations Improves 46% for Positron
08/24/2009
New York, NY, August 24, 2009-CFFO-NEWS reports that negative Cash Flow from Operations for Positron Corporation (OTC:POSC) for its quarter ended June 30, 2009 was $(547,000), a 46% improvement over the year earlier same quarter when Positron generated $(1,021,000) in negative Cash Flow from Operations. Positron has generated twenty-one consecutive quarters of negative Cash Flow from Operations.
For Positron's twelve months ended June 30, 2009 Cash Flow from Operations was $(2,661,000), compared with $(3,561,000), a 25% improvement over the comparable year earlier twelve months.
The shares of Positron were recently trading at $0.08 which is within 6% of their one year high of $0.09 on August 29, 2008.
The CFFO-NEWS utilizes a line item which is labeled as �Operating Cash Flow�, �Cash Flow From Operations� or �CFFO�, which can be found within a company�s Cash Flow Statement to calculate Cash Flow From Operations. The Cash Flow Statement is filed with the Securities & Exchange Commission on a quarterly basis.
The CFFO-NEWS monitors and publishes quarterly updates on Cash Flow From Operations for over 8,000 publicly traded U.S. companies. It also follows and publishes articles and reports on 216 industry groups. The CFFO-NEWS�s company news, industry news and archives are available at www.StockTrendNews.com.
looks like somethng big is going on. a few more days like this and we will be .12 or .15
Cardinal Health buys imaging company Biotech
http://finance.yahoo.com/news/Cardinal-Health-buys-imaging-apf-2947993368.html?x=0&.v=2
COULD POSC bE NEXT???????????
POSITRON JOINS MEDAXIOM AS A CORPORATE PARTNER
INDIANAPOLIS—July 16, 2009 (BUSINESS WIRE)--Positron Corporation (OTCBB:POSC.OB - News) (the “Company”), a molecular imaging solutions company focused on Nuclear Cardiology, announced today that they have signed on as a Corporate Partner with MedAxiom. MedAxiom is a comprehensive subscription-based service provider and information resource exclusively for cardiology practices. MedAxiom’s network is compiled of over 300 practices representing 5,400 physicians covering 45 states across the U.S. MedAxiom is a community of cardiology practice executives, administrative leaders, physicians and business office teams that strive to be more effective and efficient through sharing of operational practice data, best practice business strategies, positive and negative experiences as well as insights into the future of cardiology.
“Aligning with MedAxiom provides Positron direct access to most all cardiology practices in the country and many that are in the immediate market for Positron’s products,” stated Mark Wilson, Director of Business Development for Positron Corporation. “The MedAxiom membership is our exact target market. The products and services which Positron provides truly benefit the types of cardiology groups that make up the MedAxiom membership and community. Positron’s solutions for PET and SPECT address the evolving market conditions that face all cardiology groups today.”
“The new Corporate Partnership between MedAxiom and Positron is a timely one and we’re very excited to help bring the Positron technology to our member practices. Because of the Mo99 shortage, more MedAxiom members are being forced to look at alternative clinical options such as PET” said Chris Romeo, Vice President of Corporate Relations. “The recent 510(k) approval of the Positron PET scanner, the Attrius™, now allows for this proven technology (PET) to be delivered to the cardiology practice environment in a much more affordable means.”
Great news for POSC
In recent months we have seen a number of developments in the nuclear medicine industry that further validates Positron’s position as a solution for better medicine, better business enterprise models for physicians and cost efficiencies for insurance payers. The following is a big step in the direction that PET is in demand.
The Chalk River reactor will not be back in service till the end of the year at best. The speed in the timing of the migration to PET has greatly increased.
We believe that the shift in PET that we expected in the future has arrived. Access to PET scanners is a very hot topic all over and per this article that confirms our consultants position that Canada is a very large market as it has so few PET’s and that due to Health Canada’s needs to supply the whole country access to equal medicine the numbers can be huge. The estimation on amount of cameras needed country wide is approximately 700-900. We will continue to ramp up our efforts in Canada at this time.
READ THE ARTICLE HERE: http://thesudburystar.com/ArticleDisplay.aspx?e=1648561
POSC announced today that Peter Webner RT(N), CNMT has joined Positron in the capacity of Northeast Regional Business Director. Mr. Webner brings over 20 years of experience in the Nuclear Medicine field. Mr. Webner has built extensive relationships in the field and is active in promoting nuclear medicine on a global basis.
"Peter’s overall expertise and clinical background in Nuclear Medicine will significantly enhance our management team and bottom line," said John Zehner, COO and VP of Sales. "I have known Peter for the past decade, his understanding of the industry, clinical knowledge and his ability to always be ahead of the curve has made him a tremendous addition to our team. Peter has the proven ability to assist both our customers and companies in all facets of their patient care, business development and revenue growth.”
Most recently, Mr. Webner served as Vice President Product Development for IBA North America – Ion Beam Applications is a global provider of healthcare solutions with PET and SPECT applications. During his nine year tenure at IBA, he launched the North East market and had significant impact on increasing revenue, margins and earnings. He led initiatives to increase new product development efforts, such as, a mobile Rb-82 generator sharing plan for Cardiac imaging and was extensively involved in product acquisitions for IBA.
“This is an incredible opportunity to expand my career in Nuclear Medicine. Positron has an outstanding line of products,” stated Peter Webner. “The recently approved 510k Attrius PET scanner, the Pulse® SPECT scanner, the new Tech-Assist™, and the new Nuclear Pharm-Assist® provide imaging and automation solutions. The entire product line utilizes state of the art technology to deliver practical, safe, and cost effective care and work flow solutions to our industry for both Cardiac and Oncology applications.”
Mr. Webner currently serves on the Society of Nuclear Medicine’s PET Utilization Task force, Reimbursement Committee, and APC Task force. He also serves on the Academy of Molecular Imaging’s Referring Physician Education Workgroup, Reimbursement, and Health Economics Workgroup.
About Positron
Positron is a molecular imaging company with a focus on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron has four primary products: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical patient injection shield. Over 150 Positron products are installed in hospitals and medical offices around the world. More information about Positron is available at www.positron.com.
Here are a few news stories on APCU
09 22 2008 KTUU NBC News Story
link:
POSC is going to .20 or higher after the conference in June.
IMO
POSC interview on moneytv.net
MoneyTV with Donald Baillargeon, Week of 5/8
On Friday May 8, 2009, 5:00 am EDT
LOS ANGELES, CA--(MARKET WIRE)--May 8, 2009 -- MoneyTV, hosted by anchor Donald Baillargeon, is the internationally syndicated television program all about money and what makes it happen, (http://www.moneytv.net), featuring informative interviews with company CEOs, providing insights into their operations and outlooks for their futures.
Free information packages from the featured companies can be requested by sending an email to info@moneytv.net.
The television program can also be viewed online immediately at www.moneytv.net.
Featured companies on this week's program include:
Positron Corporation (OTC BB:POSC.OB - News) Spokesperson James Farinella announced the company had received FDA approval for their Attrius Cardiac PET scanner.
XsunX, Inc. (OTC BB:XSNX.OB - News) CEO Tom Djokovich answered what he said were lately, the two most frequently asked questions of him.
OriginOil, Inc. (OTC BB:OOIL.OB - News) CEO Riggs Eckelberry announced a breakthrough in algae extraction for oil production and the steps the company has taken with regards to patent protection.
The Mortgage Minute Guy Roger Schlesinger told why he feels the real estate market is on the rebound.
Viewers of MoneyTV can receive free information in the mail about featured companies by calling the toll-free phone number on their TV screen. The weekly television program debuted in 1996 and is broadcast nationally in the USA to 70 million U.S. homes on Saturdays at 11:00 AM ET, Sundays at 8:30 AM PT, 8:30 AM ET, 9:30 AM ET, 3:30 PM ET and Mondays at 6:30 PM ET.
MoneyTV is broadcast to 45 million TV homes in Western Europe, Wednesdays at 5:00 PM, on UPN-TV in the Virgin Islands and Puerto Rico Sundays at 8:00 AM and is also available in Thailand on the Broad TV Network. The program airs eight times per week in the 21 Caribbean Territories on CaribVision Network.
A complete menu of TV listings is available at the MoneyTV web site, http://www.moneytv.net.
MoneyTV Executive Producer and Anchor Don Baillargeon is also the host of the radio program MoneyRap Radio, http://www.moneyrap.com and the television show Health This Week, http://www.healththisweek.com.
POSC recieves FDA Approval!!
Press Release Source: Positron Corporation
Positron Joint Venture Receives FDA Approval for AttriusTM Scanner Product Line
Thursday April 30, 2009, 1:28 pm EDT
INDIANAPOLIS--(BUSINESS WIRE)--Positron Corporation (OTCBB:POSC - News)(the “Company”), a cardiac molecular imaging solutions company, announced today that the United States Food and Drug Administration (FDA) has approved Neusoft Positron Medical Systems 510(k) submission for its Attrius™ Positron Emission Tomography (PET) scanner product line developed by the Company and its joint venture with Neusoft Medical Systems based in Shenyang, China. Positron’s Attrius™ product line was developed to provide physicians a state of the art cardiac PET molecular imaging system. The AttriusTM scanner comes complete with a feature set designed specifically for cardiac perfusion imaging such as a coronary artery disease software suite that includes; mercator projections, normal database comparison, coronary artery tree and distribution overlay map, rapid segmented attenuation correction, motion correction, and open acquisition architecture for today’s challenging quantitative flow reserve imaging.
Joseph Oliverio, President of Positron states that "We believe that a significant market demand exists for a technology improvement in nuclear cardiology at an affordable cost of entry. Our Attrius device was specifically developed for cardiac molecular imaging and can provide patients with an accurate diagnosis resulting in cost savings to our healthcare system, the ability to track the efficacy of therapy, the potential for improved patient outcomes and help emergency room physicians see the result of a patient’s chest pain without the need for an angiogram. This FDA approval allows us to immediately ramp up our sales & marketing efforts as we will offer the Attrius™ to the more than 4,000 cardiology offices and 3,000 target hospitals. The Company feels its Attrius™ PET scanner is the solution that thousands of cardiology groups are looking for to improve their bottom line, reduce healthcare costs and provide patients with a superior diagnosis of coronary artery disease.”
About Positron
Positron Corporation is a vertically integrated company in the field of Cardiac Nuclear Medicine. The Company operates through two segments: Radiopharmaceutical Products and Molecular Imaging Devices. The Pharmaceutical Products segment offers world’s first robotic systems (Nuclear Pharm-Assist® & Cardio-Assist™) for distribution and delivery of radiopharmaceuticals and provides radiopharmaceutical agents used for the diagnosis of cardiac diseases; the Molecular Imaging Devices segment provides PET scanners (Attrius™) and SPECT cameras (Pulse®);. Positron’s SPECT and PET cardiac molecular imaging systems and radiopharmaceutical deliver devices are installed in more than 150 hospitals and physician offices around the world. Additional information may be found at http://www.positron.com.
Forward Looking Statements:
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.
For further information please contact Positron Corporation at (866)-613-7587
why do you think that?
90 mill out X .0016 = SARO is worth $144K
why bother?
on the other hand if it dosent get approved i dont know if it will get announced as a rejection i dont know how that works
i thought is was much more.
i am thinking there may have been some short positions
who knows?